ArticleBlood cancer journal2017

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

X Leleu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.